July 14, 2004

FOR: ZOLL Medical Corporation

Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832



Wednesday, July 14, 2004 – CHELMSFORD, MASS.—ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and software solutions, announced today that Boral Industries, Inc., based in Atlanta, purchased 120 ZOLL AED Plus™ automated external defibrillators (AEDs) for deployment in its 116 manufacturing, distribution and retail facilities. The purchase, completed through ZOLL’s distributor SEMA Medical, also includes training at some locations, maintenance, and medical oversight provided by Premedics™ Inc., a leading AED services provider.

According to Scott Herndon, a Boral Industries’ Regional Safety Manager, “We chose the ZOLL AED Plus because it is easy to use during a rescue. We also believe its unique ability to provide instant feedback during CPR makes it the best AED to help our employees who find themselves involved in a cardiac arrest event. The AED program we are establishing is a very important step in supporting the health and welfare of our 1,800 employees in 16 states across the U.S.”

“With every passing minute after sudden cardiac arrest (SCA) occurs, a victim’s chance of survival decreases by 10 percent. Due to this limited timeframe, AEDs in the workplace are essential because many factors—from large corporate campuses to heavy urban traffic—can make it challenging for emergency medical services to arrive in time to successfully treat an SCA victim,” said Richard A. Packer, President and Chief Executive Officer of ZOLL. “Progressive organizations, such as Boral Industries, have implemented AED programs to protect their employees, but they are still in the minority. It is important to educate and train employers about the value of AEDs on site so that they are better prepared to deal with someone suffering from SCA.”

When a victim collapses from SCA, rescuers do not know whether defibrillation or CPR is the appropriate therapy until an AED is attached and the victim’s heart is analyzed. About half of all victims that suddenly collapse initially require defibrillation. For other victims, however, who may have non-shockable heart rhythms, the critical action for survival is effective CPR.

The ZOLL AED Plus is the only AED that helps rescuers perform effective CPR because it allows them to see and hear how well they are performing the rate and depth of chest compressions during CPR. This real-time feedback mechanism makes the ZOLL AED Plus the only AED that can help assess and treat nearly every sudden cardiac arrest victim, making it the only Full-Rescue AED available today.

Study results, announced at the 2004 National Association of EMS Physicians Conference, showed that lay rescuers followed more steps in the Chain of Survival using the AED Plus than other available AEDs. In addition, the AED Plus helped study participants significantly improve chest compressions during CPR, with an average 250% increase in the depth of compression. There was no improvement in compressions with any other device used in the study. The study suggests AEDs that provide support-prompts to assist with carrying out steps in the Chain of Survival may help achieve higher survival rates for out-of-hospital cardiac arrest.

About ZOLL Medical Corporation
ZOLL Medical Corporation (NASDAQ: ZOLL) designs, manufactures, markets, and/or sells non-invasive resuscitation devices and software solutions. They include pacing and defibrillation devices (ZOLL’s M Series™ and AED Plus™, and LIFECOR, Inc.’s LifeVest™ Wearable Defibrillator), circulatory assist devices (Advanced Circulatory Systems, Inc.’s ResQPOD™ Circulatory Enhancer and Revivant Corporation’s AutoPulse™); and a fluid resuscitation product called the Power Infuser®, manufactured by Infusion Dynamics, a division of ZOLL. These devices help healthcare professionals, emergency medical service providers, and first responders diagnose and treat victims of trauma, as well as sudden cardiac arrest.

Additionally, through its subsidiary ZOLL Data Systems, ZOLL designs and markets software that automates the collection and management of both clinical and non-clinical data. With direct operations, international offices, and business partners in all of the world’s major markets, ZOLL markets and sells its products in more than 140 countries. For more information, visit www.zoll.com or call +1 (978) 421-9655.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company’s business, our ability to differentiate our products from others on the market, and other statements contained herein regarding matters that are not historical facts, are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled "Risk Factors" in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 19, 2004.

Copyright © 2004 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AED Plus, M Series, and Power Infuser are trademarks of ZOLL Medical Corporation. The LifeVest System is a trademark of LIFECOR, Inc. The ResQPOD is a trademark of Advanced Circulatory Systems, Inc. The AutoPulse Resuscitation System is a trademark of Revivant Corporation. ZOLL is a registered trademark of ZOLL Medical Corporation. All trademarks are property of their respective owners.